Retrospective Cohort Study
Copyright ©The Author(s) 2021.
World J Clin Cases. Dec 6, 2021; 9(34): 10472-10483
Published online Dec 6, 2021. doi: 10.12998/wjcc.v9.i34.10472
Table 1 Intestinal metaplasia and atrophic gastritis regression based on intention-to-treat and per-protocol analyses
GroupIM regression (%)
AG regression (%)
IM or AG regression (%)
ITT analysis
PP analysis
ITT analysis
PP analysis
ITT analysis
PP analysis
LTEVB12 initial therapy 39.9452.9536.3948.2453.5570.98
Celecoxib rescue therapy 30.0056.2527.5051.5639.1778.33
Complete therapy50.5985.93----
Table 2 Intestinal metaplasia and atrophic gastritis regression rates of different operative link on gastritis assessment and operative link on gastric intestinal metaplasia assessment stages for each therapy group
GroupIM regression (%)
AG regression (%)
Ⅰ stage
Ⅱ stage
Ⅲ stage
Ⅳ stage
P value
Ⅰ stage
Ⅱ stage
Ⅲ stage
Ⅳ stage
P value
LTEVB1217.1957.27a70.97a89.47a,b< 0.00133.3340.6366.67100.00c,d< 0.05
Celecoxib57.1431.3771.60e71.43e< 0.001-30.0050.0076.20f< 0.05
Table 3 Factors associated with regression of intestinal metaplasia and atrophic gastritis (multivariate analysis)
Regression effect
Factor
LTEVB12
Celecoxib
OR
95%CI
P value
OR
95%CI
P value
IMFresh vegetable intake (> 100 g/d)0.4970.224-1.1050.087---
High salt diet 1.8521.044-3.2850.035---
Tea intake (> 100g/d)---2.2950.736-7.1580.152
Education level (≥ senior high school)---1.6720.495-5.6430.408
Income level (≥ 5000 yuan/mo)---3.0970.902-10.6380.073
AGEducation level (≥ senior high school)0.4800.255-0.9030.023---
Tea intake (> 100g/d)0.6780.388-1.1850.173---
Profession (ref: Farmer)0.169-
Officer0.7840.313-1.9650.603---
Medic------
Teacher1.8970.620-5.8040.262---
Merchant1.0280.361-2.9330.958---
Technical staff3.3051.275-8.5650.014---
Retired1.8780.791-4.4580.153---
Unemployed1.5700.612-4.0270.348---
Blood type (ref: A)-0.123
B---2.0210.240-17.0330.518
O---0.3220.064-1.6170.169
AB---0.1180.010-1.4600.096
Unknown---0.3890.128-1.1820.096